Shay Tamari serves as Medison’s Chief Business Officer, helping advance the company’s mission to accelerate access to breakthrough therapies in markets beyond the U.S., Western Europe, and Japan. He brings over 20 years of global leadership experience in the biopharmaceutical industry and a strong track record in corporate strategy, business development, and deal-making with biotech partners.
Shay joined Medison from Pfizer, where he spent a decade in a range of strategic business development roles, including  Vice President, Head of Pfizer’s Corporate Development. In this role, Shay led strategic initiatives, key partnerships, mergers & acquisitions and new company creation. Earlier in his career, Shay held strategic and business development roles at Baxter and Shire. With a strong focus on global expansion and building high-performing teams, Shay generated long-term value through trusted, results-driven collaborations.
At Medison, Shay plays a central role in advancing our proprietary global commercialization platform, leading the Business Development team to strengthen biotech partnerships, expand reach, and continue to position Medison as the strategic partner of choice for biotechs aiming to bring breakthrough therapies to patients in need.
Based in New York, Shay works closely with key biotech hubs to amplify Medison’s presence and impact across the global life sciences ecosystem.
Shay holds a BA from the College of Management and an MBA from Columbia University.